ASCO: Targeted Duo Boosts OS in Melanoma

CHICAGO (MedPage Today) -- Adding a growth factor to the immune-stimulating drug ipilimumab significantly improved overall survival (OS) in patients with metastatic melanoma, a proof-of-principal phase II study showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/06/asco-targeted-duo-boosts-os-in-melanoma.html